Chronic Respiratory Disease is a leading peer-reviewed journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by SAGE Publications Ltd since its inception in 2004, this open-access journal has been at the forefront of disseminating high-quality research aimed at addressing chronic respiratory conditions. With an impressive impact factor and classified as Q1 in the 2023 category of Pulmonary and Respiratory Medicine, it ranks an admirable #45 out of 155 in Scopus, placing it in the 71st percentile of its field. This journal features a diverse range of studies, reviews, and clinical insights that cater to researchers, healthcare professionals, and students alike, encouraging the exchange of innovative ideas and practices in respiratory disease management. Operating out of London, UK, Chronic Respiratory Disease exemplifies a commitment to openness, having transitioned to open access since 2017, thereby ensuring that pivotal research is readily accessible to a global audience engaged in the improvement of respiratory health.

Respiratory Medicine is a leading journal in the field of pulmonary and respiratory medicine, dedicated to advancing knowledge and research from 1989 to 2024. Published by W B Saunders Co Ltd, this esteemed journal is recognized for its high impact, reflected in its Q1 quartile ranking in 2023 within the category of Pulmonary and Respiratory Medicine and its impressive Scopus ranking of 27 out of 155 journals, placing it in the 82nd percentile. With a focus on publishing groundbreaking research, comprehensive reviews, and innovative practices, Respiratory Medicine serves as an essential resource for health professionals, researchers, and students aiming to improve patient outcomes and understand complex respiratory conditions. While the journal is not Open Access, its contributions to the scientific community are invaluable, providing insights that drive both academic and clinical advancements in respiratory health.

Thoracic Research and Practice is an emerging open access journal published by AVES that aims to advance knowledge in the field of pulmonary and respiratory medicine. Launched in 2022, this journal aspires to provide a platform for innovative research, clinical practices, and advancements in thoracic health. With an E-ISSN of 2979-9139, it caters to a global audience while based in Turkey. Although it currently holds a Q4 category in the 2023 ranking within its field, the journal is dedicated to improving its standing through the inclusion of high-quality, original articles, systematic reviews, and case studies. As it converges years from 2023 to 2024, Thoracic Research and Practice invites researchers, professionals, and students to contribute valuable insights that aim to enhance patient outcomes and propel further exploration in this critical area of medicine.

Annals of Thoracic Medicine is a prominent open-access journal, published by Wolters Kluwer Medknow Publications, focusing on the critical fields of cardiology, pulmonary and respiratory medicine, and surgery. With an ISSN of 1817-1737 and an E-ISSN of 1998-3557, this journal aims to disseminate cutting-edge research, clinical findings, and innovative practices that can significantly impact the health outcomes of patients dealing with thoracic diseases. Since its inception in 2006, it has established itself as a reputable source of knowledge, achieving Q2 quartile rankings in 2023 across its main categories. Currently ranked #126 in Medicine & Surgery and exhibiting a growing SCOPUS percentile, the journal plays an essential role in advancing the understanding and treatment of thoracic conditions. Open access options ensure that research is readily available to a global audience, facilitating collaboration and knowledge sharing among researchers, healthcare professionals, and students in the field.

American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society, is a leading scholarly journal dedicated to advancing the fields of critical care and pulmonary medicine. With an impressive impact factor and recognized in the Q1 quartile for both Critical Care and Pulmonary Medicine, this journal is essential reading for researchers, clinicians, and students invested in innovative practices and therapies in respiratory health. Through high-quality, peer-reviewed research articles, the journal addresses significant contemporary issues in respiratory and critical care, offering unparalleled insights and fostering interdisciplinary collaboration. Although the journal adheres to a traditional subscription model, it remains a cornerstone for those wishing to stay at the forefront of medical science in this vital area. With its extensive historical context since its establishment in 1991 and continuous publication spanning through 2024, the journal is committed to promoting discourse and disseminating knowledge that ultimately enhances patient care and clinical outcomes.

ERJ Open Research is a distinguished Open Access journal dedicated to advancing the field of pulmonary and respiratory medicine, published by the European Respiratory Society Journals Ltd. Established in 2015, the journal proudly provides a platform for innovative research and comprehensive studies that address vital questions in respiratory health. With an impressive Q1 ranking in Scopus for Pulmonary and Respiratory Medicine and positioned in the top 73rd percentile among its peers, ERJ Open Research is a critical resource for researchers, clinicians, and students alike. The journal’s commitment to open access ensures that high-quality research is readily available to the global community, fostering collaboration and knowledge-sharing. Whether you are looking to publish groundbreaking findings or stay updated on the latest advancements in respiratory medicine, ERJ Open Research is the premier destination for impactful scholarly contributions.

Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.

Respiratory Medicine and Research, published by Elsevier, is a pivotal journal in the field of Pulmonary and Respiratory Medicine, dedicated to advancing the understanding and treatment of respiratory diseases. Since its inception in 2019, the journal has provided a platform for high-quality research, contributing significantly to the scientific community's knowledge base, as reflected in its impressive Q2 categorization in 2023. With a Scopus rank of #94 out of 155, placing it in the 39th percentile, this journal is essential for researchers, professionals, and students seeking the latest advancements in respiratory medicine. Although currently categorized as a non-open access publication, it remains accessible to those affiliated with institutions with subscriptions. Published in France, the journal aims to foster collaboration and innovation by highlighting original research, clinical studies, and comprehensive reviews that address pressing issues in respiratory health.

Therapeutic Advances in Respiratory Disease is a prestigious open-access journal published by SAGE Publications Ltd, based in the United Kingdom. Since its inception in 2007, it has established itself as a leading platform for the dissemination of cutting-edge research in the fields of pulmonary and respiratory medicine and pharmacology. With an impressive impact factor and ranking—showing it is in the Q1 quartile in both Pharmacology (medical) and Pulmonary and Respiratory Medicine as of 2023—the journal's commitment to high-quality research is evident. In 2023, it ranks #32 out of 155 in Pulmonary and Respiratory Medicine and #57 out of 272 in Medical Pharmacology, positioning it in the 79th percentile across these disciplines. Open access since 2018, the journal ensures that its valuable content is readily accessible to a global audience of researchers, healthcare professionals, and students, facilitating the rapid exchange of knowledge that is crucial in the ever-evolving landscape of respiratory health. The journal's objectives include advancing understanding of respiratory diseases through innovative research and promoting the development of therapeutic strategies that improve patient outcomes, making it an essential resource for those dedicated to respiratory medicine.

Respiratory Investigation is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of Pulmonary and Respiratory Medicine. Since its inception in 2012, the journal has grown to become a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality research articles, reviews, and clinical studies. With a commendable impact factor and ranked in the Q2 category of Scopus' 2023 metrics, it stands at rank #57 out of 155 in its field, illustrating its importance and influence within the academic community. Although the journal operates on a subscription basis, it remains committed to disseminating essential findings that enhance the understanding and treatment of respiratory diseases. Set against the innovative backdrop of the Netherlands, Respiratory Investigation not only serves as a conduit for scholarly exchange but also plays a critical role in shaping future research directions and clinical practices.